Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Starling Oncology, Inc. STLN

Healthcare — Medical Care Facilities
Cash Flow Champion (3y) Insider Buys (last 12m)
Growth Flags show if company had growth for consecutive years ,
Insider Buys alert about insiders buying in the last 12 month

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total buys
2.69
Total sells
2.81
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — 5 1 2 2 2 1 —
Sell — 1 1 1 — — 1 — 1 1 1 —
Insider Ownership
38.30%

Capital & Financial Ratios

Market Cap
662.89
Revenue
587.24
Net Income
(36.29)
Free Cash Flow
(3.29)
Net Debt
38.77
Current Ratio
1.36
Debt/Equity
(3.21)
P/E ratio
0.00
P/S ratio
1.22
P/B ratio
0.00
Past 5Y EPS Growth
(488.57%)
This Y EPS Growth
69.91%
Next Y EPS Growth
100.00%
Next 5Y EPS Growth
51.70%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2020 ‡‡‡
2019 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 82.86 49.67 33.57 41.09
Receivables 42.91 48.68 59.32 66.71
Inventory 13.68 10.04 16.88 20.01
Other — — — —
143.49 112.42 112.75 128.99
2023 2024 2025 Q'26
Payables 14.43 24.32 43.17 60.28
ST’ Debt — — — —
Other — — — —
34.79 52.22 70.96 94.94
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow — ‡‡‡ ‡‡‡
Earnings — ‡‡‡ ‡‡‡
Book Value — ‡‡‡ ‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 147.44 161.28 — —
—
’25 104.41 119.80 136.56 141.96
502.73
’24 94.67 98.58 99.90 100.27
393.41
’23 76.19 80.22 82.04 85.79
324.24
’22 55.16 60.92 64.98 71.42
252.48
’21 48.58 49.84 52.28 52.30
203.00
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (2.21) 11.94 — —
—
’25 (4.99) (10.20) (12.63) 3.23
(24.59)
’24 (15.88) (15.66) 0.82 4.19
(26.54)
’23 (15.45) (8.66) (8.31) (3.89)
(36.31)
’22 (16.98) (10.38) (20.40) (14.00)
(61.76)
’21 0.46 (7.13) (2.68) (23.33)
(32.68)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (3.26) 11.03 — —
—
’25 (5.32) (11.41) (13.23) 2.17
(27.79)
’24 (16.49) (17.49) 1.22 2.43
(30.33)
’23 (17.29) (9.60) (9.24) (4.75)
(40.88)
’22 (17.98) (11.72) (21.59) (15.99)
(67.28)
’21 (0.15) (7.74) (3.63) (24.21)
(35.73)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.02) (0.08) — —
—
’25 (0.21) (0.15) (0.14) (0.06)
(0.54)
’24 (0.22) (0.17) (0.18) (0.14)
(0.71)
’23 (0.33) (0.19) (0.19) (0.21)
(0.92)
’22 0.21 (0.06) (0.17) (0.15)
(0.20)
’21 0.20 (0.21) (0.02) (0.15)
(0.16)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡
Low
‡‡‡‡‡
‡‡‡

Recommendation Rating

1
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
— — — — ‡‡‡ ‡‡‡‡ 0.86 0.33 0.13 0.25 — — —
Low Price
— — — — ‡‡‡‡ ‡‡‡‡‡ 10.74 2.66 2.50 4.88 — — —
High Price
— — — ‡‡‡ ‡‡‡ ‡‡‡‡‡ 750 800 825 641 — — —
Employees
— — — ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.34 0.41 0.48 0.78 — — —
Revenue/Emp
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 252.48 324.24 393.41 502.73 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 20.63% 18.37% 13.73% 15.20% — — —
Gross Margin
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.09) (83.10) (64.66) (60.74) — — —
EBT
— — — ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.04%) (25.63%) (16.44%) (12.08%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
— ‡‡‡ — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.15 (83.07) (64.66) (60.61) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 15.78 26.31 12.09 15.32 — — —
Depreciation
— — — ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.47 4.40 5.24 5.44 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
— — — ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.02 (0.92) (0.71) (0.54) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡
Earnings/Sh
— — — ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.85) (0.49) (0.35) (0.27) — — —
Cash Flow/Sh
— — — ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.08) (0.06) (0.05) (0.03) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
— — — ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.92) (0.55) (0.40) (0.30) — — —
Free CF/Sh
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.69 0.77 0.05 (0.17) — — —
Book Value/Sh
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 72.79 73.75 75.04 92.39 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
— — — — ‡‡‡ ‡‡‡ 80.50 0.00 0.00 0.00 ‡‡‡‡‡ ‡‡‡‡‡ —
PE Ratio
— — — — ‡‡‡ ‡‡‡‡‡ 0.46 0.52 0.06 0.65 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 0.95 2.97 6.48 0.00 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
— — — — ‡‡‡ ‡‡‡‡‡ 0.51 0.55 0.19 0.75 ‡‡‡‡ ‡‡‡ ‡‡‡‡
EV/Sales
— — — — ‡‡‡‡‡ ‡‡‡‡‡ (1.93) (4.39) (2.40) (13.63) — — —
EV/FCF
— — — — ‡‡‡‡‡ ‡‡‡‡‡ (61.76) (36.31) (26.54) (24.59) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
— — — — ‡‡‡‡‡ ‡‡‡‡‡ (5.53) (4.57) (3.79) (3.20) — — —
Capex
— — — — ‡‡‡‡‡ ‡‡‡‡‡ (67.28) (40.88) (30.33) (27.79) — — —
FCF
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 100.70 108.71 60.20 41.79 — — —
Working Cap'
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 86.20 86.83 93.13 77.40 — — —
Total Debt
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 12.40 3.97 43.46 43.84 — — —
Net Debt
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 123.18 57.03 3.59 (15.72) — — —
Sh' Equity
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.07% (35.28%) (33.86%) (35.93%) — — —
ROA
— — — ‡‡‡ ‡‡‡‡‡ ‡‡‡ (37.78%) (78.92%) (79.86%) (80.21%) — — —
ROIC
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.13% (92.20%) (213.36%) 999.19% — — —
ROE
predictions in italic, sparklines do not include predictions

Starling Oncology, Inc. (STLN) Latest News

News by impact score

Fine-tune

17 Aug

4 , 8:00 AM
Starling Oncology launches Starling Nexus technology platform to optimize oncology provider engagement and accelerate high-quality care at scale. Launch of Starling Nexus platform marks major strategic move with potential to significantly alter company trajectory and investor sentiment.

7 Aug

3 transcript www.marketbeat.com, 2:04 PM
Oncology Institute reported Q2 earnings call highlights covering financial results, operational metrics and forward outlook for the oncology services provider. Q2 earnings data and outlook directly inform near-term revenue expectations and investor sentiment for STLN.

6 Aug

3 , 7:10 PM
The Oncology Institute reported a Q2 loss while exceeding revenue estimates. Q2 earnings with a loss but revenue beat signals moderate effects on financial perception and near-term stock movement.

3 , 4:14 PM
Starling Oncology reported second quarter 2026 financial results and updated full-year 2026 guidance. Quarterly results plus guidance revision can shift near-term investor views and valuation.

7 Jul

4 , 9:00 AM
The Oncology Institute refinanced with OrbiMed and repaid its $86 million Deerfield convertible note, strengthening the balance sheet and improving liquidity. Eliminating $86M convertible debt via OrbiMed refinancing directly improves capital structure and liquidity.

3 , 3:43 AM
Analyst upgrades highlight The Oncology Institute’s (TOI) community cancer care growth story. Analyst upgrades spotlight TOI's community cancer care growth potential.

11 May

4 Simply Wall St., 12:06 PM
The Oncology Institute, Inc. (NASDAQ:TOI) released earnings last week, prompting analysts to lift their price target to US$7.00. Analyst price target increase to $7.00 following earnings release indicates strong positive sentiment likely to drive significant stock price gains and investor interest.

9 May

4 www.marketbeat.com, 1:06 AM
The Oncology Institute (TOI) released Q1 earnings call highlights, detailing financial results, patient growth, revenue increases, cost management efforts, and optimistic guidance for full-year performance amid expansion plans. Q1 earnings highlights show revenue growth and strategic expansions that significantly shape TOI's financial trajectory and investor outlook.

8 May

4 app.moby.co, 8:30 AM
The Oncology Institute, Inc. (TOI) released Q1 2026 earnings call summary, detailing financial results, operational updates, and forward guidance. Q1 2026 earnings highlights financial performance and strategic direction, poised to significantly sway TOI's market trajectory and investor outlook.

7 May

4 GlobeNewswire, 4:05 PM
The Oncology Institute, Inc. (TOI) reported first quarter 2026 financial results. Quarterly earnings releases directly shape investor sentiment, stock valuation, and future performance expectations for TOI.

3 Zacks, 7:05 PM
The Oncology Institute, Inc. (TOI) reported a Q1 loss but beat revenue estimates. Q1 loss with revenue beat affects financial performance and investor sentiment moderately.

20 Apr

3 , 9:11 AM
The Oncology Institute (TOI) stock rose sharply due to surging revenue, expanded clinic network, higher patient volumes, and improved reimbursement dynamics. Drivers of TOI's gains moderately boost financial performance and market sentiment without transformative changes.

13 Apr

4 GlobeNewswire, 9:00 AM
The Oncology Institute achieved $1.8 million in Medicare savings during CMS Enhancing Oncology Model Performance Period 3, marking significant period-over-period improvement. Achieving $1.8 million in Medicare savings with period-over-period improvement signals enhanced efficiency in value-based oncology care, boosting financial performance and investor sentiment.

17 Mar

4 transcript www.fool.com, 3:58 PM
The Oncology Institute, Inc. (TOI) released its earnings call transcript, detailing quarterly financial results, revenue figures, operational updates, challenges faced, and forward-looking guidance from management. Earnings transcripts disclose financial metrics, strategic plans, and guidance that directly sway market performance and investor confidence.

13 Mar

4 app.moby.co, 8:30 AM
The Oncology Institute, Inc. (TOI) released Q4 2025 earnings call summary detailing quarterly financial results, operational updates, and forward guidance. Q4 earnings summary discloses financial performance, strategic updates, and outlook that significantly impact TOI's valuation and market trajectory.

12 Mar

4 GuruFocus.com, 11:03 PM
The Oncology Institute (TOI) reported record Q4 2025 revenue and first profitability in earnings call highlights, driven by patient volume growth, strategic expansions, and new partnerships. Record revenue and inaugural profitability represent major financial milestones that enhance TOI's growth trajectory and investor appeal.

4 www.marketbeat.com, 9:49 PM
The Oncology Institute (TOI) released Q4 earnings call highlights, detailing financial results, operational progress, value-based care expansion, and 2024 guidance amid revenue growth and adjusted EBITDA improvements. Q4 earnings highlights disclose revenue growth, EBITDA progress, and strategic expansions that could significantly shape TOI's financial trajectory and investor confidence.

4 GlobeNewswire, 4:05 PM
The Oncology Institute, Inc. (TOI) reported fourth quarter and full year 2025 financial results and issued guidance for 2026. Earnings results and forward guidance directly shape investor expectations and stock trajectory.

12 Jan

4 GlobeNewswire, 8:00 AM
The Oncology Institute, Inc. (TOI) has reaffirmed its guidance for 2025 and provided a preliminary outlook for 2026, indicating confidence in its strategic direction and financial performance. The company aims to enhance its operational efficiency and expand its services, which may positively influence its market position and investor sentiment in the coming years. Reaffirming guidance and providing a future outlook suggests significant strategic planning that could impact TOI's market performance.

9 Jan

4 Simply Wall St.Simply Wall St.FortuneSimply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Insider Monkey, 12:13 PM
The Oncology Institute, Inc. (TOI) is strategically enhancing its capabilities by focusing on artificial intelligence talent and improving financial discipline within its boardroom. This shift aims to strengthen its competitive edge in the oncology sector, potentially leading to better operational efficiency and innovation in patient care. The company's commitment to integrating advanced technologies and sound financial practices is expected to position it favorably in a rapidly evolving healthcare landscape. Strategic moves towards AI integration and financial discipline are likely to significantly impact TOI's future performance and market positioning.

3 , 8:00 AM
The Oncology Institute, Inc. (TOI) has announced several leadership promotions aimed at enhancing its operational effectiveness and strategic direction. Key promotions include the elevation of executives in various roles, reflecting the company's commitment to growth and innovation in cancer care. These changes are expected to strengthen TOI's leadership team and support its mission to provide high-quality oncology services. Leadership promotions can moderately influence the company's operational effectiveness and strategic direction.

5 Jan

3 GlobeNewswire, 8:30 AM
The Oncology Institute, Inc. (TOI) has announced the appointment of Mark Stolper to its Board of Directors. Stolper brings extensive experience in the healthcare sector, having held various leadership roles, including as Chief Financial Officer at several prominent companies. His expertise is expected to enhance TOI's strategic direction and governance as the company continues to expand its operations in oncology care. The addition of a seasoned board member may moderately influence TOI's strategic direction and governance.

21 Nov

4 www.fool.com, 5:20 AM
The Oncology Institute, Inc. (TOI) has seen its stock price surge over 950% this year, driven by increased investor interest due to its strategic focus on expanding cancer treatment services and enhancing patient care. The company's innovative approach and potential for growth in the oncology sector have attracted attention, leading to a bullish sentiment among investors. The significant stock rally is linked to strategic moves that could alter the company's trajectory and investor sentiment.

14 Nov

4 GuruFocus.comGuruFocus.comMT Newswires, 12:06 AM
The Oncology Institute, Inc. (TOI) reported a significant revenue surge in Q3 2025, driven by increased patient volume and the integration of artificial intelligence in its operations. The company highlighted advancements in treatment protocols and improved patient outcomes, which contributed to its financial growth. TOI's strategic focus on expanding its service offerings and enhancing operational efficiency is expected to bolster its market position moving forward. The revenue surge and integration of AI are likely to significantly impact TOI's future performance and market positioning.

13 Nov

4 GlobeNewswire, 4:05 PM
The Oncology Institute, Inc. (TOI) reported its financial results for the third quarter of 2025, showcasing improved revenue and operational metrics. The company also raised its full-year guidance for 2025, indicating confidence in its growth trajectory and market position. This positive performance reflects TOI's strategic initiatives and operational efficiencies, positioning it favorably within the oncology sector. The increase in full-year guidance and strong quarterly results suggest significant positive momentum for TOI's future performance.

4 GlobeNewswire, 4:04 PM
Ascertain and The Oncology Institute, Inc. (TOI) have partnered to co-develop a 'touchless' AI automation system aimed at streamlining oncology administration processes. This innovative technology is designed to enhance operational efficiency and reduce administrative burdens within oncology practices, potentially improving patient care and resource management. The collaboration signifies a strategic move towards integrating advanced AI solutions in healthcare administration, aligning with TOI's commitment to leveraging technology for better oncology services. The partnership represents a significant strategic initiative that could enhance operational efficiency and patient care in oncology, impacting TOI's market position.

3 ZacksZacksZacksZacksMotley FoolZacks, 5:30 PM
The Oncology Institute, Inc. (TOI) reported a loss in Q3 but exceeded revenue estimates. The company's financial performance showed resilience despite challenges, indicating potential for future growth. Investors reacted positively to the revenue beat, reflecting confidence in TOI's operational strategies and market positioning. Exceeding revenue estimates suggests moderate positive influence on financial performance and market sentiment.

5 Nov

3 Zacks, 9:15 AM
Establishment Labs Holdings Inc. reported a loss in Q3 but exceeded revenue estimates, indicating a positive trend in financial performance despite the loss. The company continues to focus on growth and innovation in its product offerings, which may bolster investor confidence moving forward. The revenue beat suggests potential for improved financial performance, but the loss indicates challenges that may limit overall impact.

21 Oct

4 www.fool.com, 9:45 AM
The Oncology Institute, Inc. (TOI) has experienced a remarkable 1,000% increase in stock value, significantly outperforming major tech companies like Nvidia, Tesla, and Apple. This surge is attributed to TOI's strategic initiatives and advancements in cancer treatment, positioning the company as a leader in the oncology sector. Investors are increasingly optimistic about TOI's growth potential, driven by its innovative approaches and expanding market presence. TOI's substantial stock increase reflects significant strategic moves and advancements that could alter its market trajectory.

29 Sep

4 GlobeNewswire, 8:00 AM
The Oncology Institute, Inc. (TOI) has partnered with Protocol Behavioral Health to incorporate mental health services into its cancer care offerings. This collaboration aims to address the psychological needs of cancer patients, enhancing their overall treatment experience. By integrating mental health support, TOI seeks to improve patient outcomes and provide comprehensive care that acknowledges the emotional challenges associated with cancer treatment. Integrating mental health services into cancer care is a significant strategic move that could enhance patient outcomes and improve TOI's competitive positioning in the healthcare market.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us